Core Viewpoint - Jiujiang Shanshui Technology Co., Ltd. reported a significant increase in revenue and net profit for the first half of 2025, driven by favorable market conditions in the fine chemical sector, particularly in the dye industry [1][2][3]. Group 1: Financial Performance - The company achieved operating revenue of 305 million yuan, representing a year-on-year growth of 23.08% [1]. - The net profit attributable to shareholders was 47.77 million yuan [1]. Group 2: Market Dynamics - The fine chemical sector outperformed the basic chemical sector, with the dye industry being a highlight due to improved domestic consumption and stricter environmental regulations [2]. - Prices for dye intermediates, such as 6-nitro compounds, surged due to supply-side constraints from environmental policies and seasonal demand [2]. Group 3: Industry Characteristics - The dye intermediate industry exhibits strong stability once integrated into the downstream supply chain, with high switching costs for customers due to the specific quality requirements of dye products [3]. - The company has established long-term stable partnerships with several well-known dye enterprises, maintaining a leading market share in its segment [3]. Group 4: R&D Investment - Research and development investment increased by 42.97% year-on-year, focusing on upgrading existing products and developing high-value-added products [4]. - The company has developed a core technology system that integrates product research, process development, and equipment modification, positioning it at the forefront of the industry [4]. Group 5: Product Quality and Production Efficiency - The company’s 6-nitro products have significant quality advantages, utilizing a continuous nitration process that reduces waste and lowers environmental costs [5]. - The gross margin for 6-nitro products was 45.69%, reflecting an increase compared to the previous year [5]. - The company is actively promoting the capacity release of chlorinated pyridine series products, with a gross margin of 26.33% for 2,3-dichloropyridine, showing substantial growth [5].

Core Viewpoint - The company has completed certain fundraising projects and plans to permanently supplement its working capital with the remaining funds, which is deemed a prudent decision to enhance fund utilization efficiency and reduce financial costs [5][6]. Group 1: Fundraising and Project Overview - The company raised a total of RMB 1,494,431,000 through its initial public offering, with a net amount of RMB 1,383,972,305 after deducting issuance costs [1]. - The fundraising was allocated to various projects, including a construction project for a research and development building [2]. Group 2: Fund Management and Usage - The "R&D Building Construction Project" has reached the predetermined usable state, meeting the completion criteria as of June 11, 2025 [3]. - The remaining funds from the project, amounting to RMB 42,181,900 (including interest income), will be permanently supplemented into working capital [4]. Group 3: Reasons for Fund Surplus - The company adhered to regulations regarding the use of raised funds and optimized resource allocation, leading to cost reductions in project construction [4]. - The decision to replace high-cost imported equipment with more cost-effective domestic alternatives contributed to the surplus [4]. Group 4: Impact of Fund Allocation - The permanent allocation of surplus funds to working capital is aligned with the company's operational needs and is expected to improve fund utilization efficiency without adversely affecting normal operations [5]. Group 5: Approval Process - The decision to conclude the fundraising projects and allocate surplus funds was approved in meetings held on June 13, 2025, and is pending shareholder approval [5]. Group 6: Sponsor's Verification Opinion - The sponsor, Zhongyuan Securities, has no objections to the company's decision regarding the completion of fundraising projects and the permanent allocation of surplus funds, confirming compliance with relevant regulations [6].